Old prostate drug may spark brain cells in Parkinson's
NCT ID NCT07288450
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether terazosin, a drug currently used for an enlarged prostate, can boost energy production in brain cells of people with early Parkinson's disease. One hundred participants will receive either terazosin or a placebo for 6 months. Researchers will measure changes in energy molecules in the blood and brain to see if the drug hits its target.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Terazosin Hydrochloride
What this could lead to
If it works, this could point toward a treatment that slows Parkinson's by improving brain cell energy.
What could go wrong
This is a very early Phase 1/2 trial with only 100 people. It tests whether the drug hits its target in the body, not whether it improves symptoms. Many early trials do not lead to effective treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PARKINSON'S DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••